Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.

ABSTRACT:

Background & aims

The albumin-bilirubin (ALBI) grade/score is derived from a validated nomogram to objectively assess prognosis and liver function in patients with hepatocellular carcinoma (HCC). In this post hoc analysis, we assessed prognosis in terms of survival by baseline ALBI grade and monitored liver function during treatment with ramucirumab or placebo using the ALBI score in patients with advanced HCC.

Methods

Patients with advanced HCC, Child-Pugh class A with prior sorafenib treatment were randomised in REACH trials to receive ramucirumab 8 mg/kg or placebo every 2 weeks. Data were analysed by trial and as a meta-analysis of individual patient-level data (pooled population) from REACH (alpha-fetoprotein ≥400 ng/ml) and REACH-2. Patients from REACH with Chil

SUBMITTER: Kudo M 

PROVIDER: S-EPMC7772786 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature